SMT set to take “highly deliverable” stent across Europe, India this month

PT Jyothi Datta Mumbai | Updated on July 11, 2019 Published on July 11, 2019

Representative image   -  Getty Images/iStockphoto

Supraflex Cruz is a Sirolimus eluting stent built on a Cobalt Chromium Platform

Indian stent-maker SMT or Sahajanand Medical Technologies has said it was ready to make its new and “highly deliverable” version of the Supraflex drug-eluting stent commercially available in Europe from Thursday.

This development comes after the Supraflex Cruz received the approval (CE mark) from the European regulatory recently . In fact, a little less than a year ago, a study in Europe found that the Supraflex stent system could be compared to Abbott’s Xience stent.

The stent only involved a change in design, making it more deliverable and thus “substantially” reducing procedure time for doctors and patients, SMT Chief Executive Ganesh Sabat told BusinessLine.

Supraflex Cruz is a Sirolimus eluting stent built on a Cobalt Chromium Platform and has been implanted in more than 2,50,000 patients in select Indian centres and certain international markets over the last three years. “The drug and polymer have not been changed,” he said. The company is also looking to increase the availability of the new product in India as well.

Stents are wire-like products used to unclog arteries. Deploying a stent can be difficult if the arteries are highly calcified or present in a location that was too deep, said Sabat, adding that companies were constantly innovating on design to make their stents easily deliverable.

The new product would find acceptance in Europe, he explained, because of an elderly population who may have more complicated arteries and who would not be able to spend too much time in an operation theatre.

India, beyond price control

“The Gujarat-based company had also started discussions with Indian hospitals, even as the price of stents have been capped by the Government at about Rs 30,000 odd,” said Sabat.

“We are not averse to bringing our best innovation to India even with the price cap,” he said.” He was referring to multi-national companies who have discontinued or said that price controls inhibited them from brining their best products into the Indian market.

Between price control, the Centre’s Ayushman Bharat health insurance programme and the increase in the number of cath-labs in the country, the access to stents has improved, he said.

Citing industry data, he added that last year about 230 new cath-labs were set-up across the countryincluding Uttar Pradesh, Jammu and Kashmir and the North-East.

While pricing dominates the conversation around stents in India, Sabat clarified that his pitch in Europe was not of being a “low-cost” stent but a competent, quality product with scientific results comparable to the best in class. “We are not going to start a price war,” he said, adding that they were open to discussions if Government of other health systems wanted to procure the product from them.

Further clinical studies on Cruz are planned across Europe, India, Latin America and rest of the world over the next two years, SMT said. There were to test Supraflex Cruz in a “challenging patient population” including diabetics, high-bleeding risk patients and fragile patients aged over 75years, the company said.

Published on July 11, 2019

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!


Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.